Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 37

1.

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.

Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.

Eur Child Adolesc Psychiatry. 2017 Aug;26(8):875-897. doi: 10.1007/s00787-017-0962-6. Epub 2017 Mar 3. Review.

2.

A critical appraisal of atomoxetine in the management of ADHD.

Childress AC.

Ther Clin Risk Manag. 2015 Dec 23;12:27-39. doi: 10.2147/TCRM.S59270. eCollection 2016. Review.

3.

Variants of Dopamine Beta Hydroxylase Gene Moderate Atomoxetine Response in Children with Attention-Deficit/Hyperactivity Disorder.

Fang Y, Ji N, Cao Q, Su Y, Chen M, Wang Y, Yang L.

J Child Adolesc Psychopharmacol. 2015 Oct;25(8):625-32. doi: 10.1089/cap.2014.0178. Epub 2015 Oct 8.

4.
5.

Meta-analysis of suicide-related behavior or ideation in child, adolescent, and adult patients treated with atomoxetine.

Bangs ME, Wietecha LA, Wang S, Buchanan AS, Kelsey DK.

J Child Adolesc Psychopharmacol. 2014 Oct;24(8):426-34. doi: 10.1089/cap.2014.0005. Epub 2014 Jul 14.

6.

Behavioural sleep problems in children with attention-deficit/hyperactivity disorder (ADHD): protocol for a prospective cohort study.

Lycett K, Sciberras E, Mensah FK, Gulenc A, Hiscock H.

BMJ Open. 2014 Feb 12;4(2):e004070. doi: 10.1136/bmjopen-2013-004070.

7.

Pharmacological treatment for attention deficit hyperactivity disorder: functional outcomes in children and adolescents from non-Western countries.

Altin M, El-Shafei AA, Yu M, Desaiah D, Treuer T, Zavadenko N, Gao HY.

Drugs Context. 2013 Sep 13;2013:212260. doi: 10.7573/dic.212260. eCollection 2013 Sep 13.

8.

The weighed core symptom scale and prediction of ADHD in adults - objective measures of remission and response to treatment with methylphenidate.

Edebol H, Helldin L, Norlander T.

Clin Pract Epidemiol Ment Health. 2013 Oct 18;9:171-9. doi: 10.2174/1745017901309010171. eCollection 2013.

9.

Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.

Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.

CNS Drugs. 2013 Nov;27(11):943-53. doi: 10.1007/s40263-013-0102-x.

10.

Drug therapy of attention deficit hyperactivity disorder: current trends.

De Sousa A, Kalra G.

Mens Sana Monogr. 2012 Jan;10(1):45-69. doi: 10.4103/0973-1229.87261.

11.

Remission in children and adolescents diagnosed with attention-deficit/hyperactivity disorder via an effective and tolerable titration scheme for osmotic release oral system methylphenidate.

Chou WJ, Chen SJ, Chen YS, Liang HY, Lin CC, Tang CS, Huang YS, Yeh CB, Chou MC, Lin DY, Hou PH, Wu YY, Liu HJ, Huang YF, Hwang KL, Chan CH, Pan CH, Chang HL, Huang CF, Hsu JW.

J Child Adolesc Psychopharmacol. 2012 Jun;22(3):215-25. doi: 10.1089/cap.2011.0006. Epub 2012 Apr 26.

13.

Time courses of improvement and symptom remission in children treated with atomoxetine for attention-deficit/hyperactivity disorder: analysis of Canadian open-label studies.

Dickson RA, Maki E, Gibbins C, Gutkin SW, Turgay A, Weiss MD.

Child Adolesc Psychiatry Ment Health. 2011 May 11;5:14. doi: 10.1186/1753-2000-5-14.

14.

A randomized controlled trial investigation of a non-stimulant in attention deficit hyperactivity disorder (ACTION): rationale and design.

Tsang TW, Kohn MR, Hermens DF, Clarke SD, Clark CR, Efron D, Cranswick N, Lamb C, Williams LM.

Trials. 2011 Mar 13;12:77. doi: 10.1186/1745-6215-12-77.

15.

Impact of atomoxetine on subjective attention and memory difficulties in perimenopausal and postmenopausal women.

Epperson CN, Pittman B, Czarkowski KA, Bradley J, Quinlan DM, Brown TE.

Menopause. 2011 May;18(5):542-8. doi: 10.1097/gme.0b013e3181fcafd6.

16.

Study protocol: the sleeping sound with attention-deficit/hyperactivity disorder project.

Sciberras E, Efron D, Gerner B, Davey M, Mensah F, Oberklaid F, Hiscock H.

BMC Pediatr. 2010 Dec 30;10:101. doi: 10.1186/1471-2431-10-101.

18.

Strattera: ups, downs, and emerging uses.

Cascade EF, Kalali AH, Feifel D.

Psychiatry (Edgmont). 2007 Apr;4(4):23-5.

19.

An atomoxetine tutorial.

Feifel D.

Psychiatry (Edgmont). 2007 Aug;4(8):35-8. No abstract available.

20.

Self-esteem in adolescent patients with attention-deficit/hyperactivity disorder during open-label atomoxetine treatment: psychometric evaluation of the Rosenberg Self-Esteem Scale and clinical findings.

Dittmann RW, Wehmeier PM, Schacht A, Lehmann M, Lehmkuhl G.

Atten Defic Hyperact Disord. 2009 Dec;1(2):187-200. doi: 10.1007/s12402-009-0011-5. Epub 2009 Sep 23.

Supplemental Content

Support Center